RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.
RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancers, including colorectal and gastric cancer.
Science underlying Rgenix’s technology and pipeline has been published in leading scientific journals.
Immuno-Oncology 360° | Crown Plaza Time Square, New York City | February 6, 2019 Masoud Tavazoie, Rgenix CEO and Co-Founder
Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting
On November 28, 2018, Masoud Tavazoie, Co-Founder and CEO of Rgenix, made a presentation at AACR’s Tumor Immunology and